受体酪氨酸激酶AXL在肿瘤中的研究进展

doi:10.11904/j.issn.1002-3070.2017.03.019

摘要/Abstract

摘要： AXL是TAM受体酪氨酸激酶家族中的一员,AXL已经被证实与肺癌、乳腺癌、甲状腺癌、前列腺癌和胰腺癌等多种癌症有关。最新证据显示,AXL可促进多种肿瘤的生长、侵袭、转移,其抑制剂可抑制肿瘤形成,这说明AXL可能成为抗肿瘤治疗的潜在靶点,AXL激酶抑制剂的应用可能成为抗肿瘤治疗的新策略。本文对AXL与肿瘤方向的研究进展做一综述。

关键词: 受体酪氨酸激酶, AXL, 肿瘤, ALX激酶抑制剂

Abstract: AXL is a member of the TAM receptor tyrosine kinase family,and AXL has been shown to be associated with a variety of cancers such as lung cancer,breast cancer,thyroid cancer,prostate cancer and pancreatic cancer.The latest evidence suggests that AXL can promote the growth,invasion and metastasis of various tumors,and its inhibitors can also inhibit tumor formation,suggesting that AXL may be a potential target for anti-tumor therapy,and the use of AXL kinase inhibitors may become the new strategy of anti-tumor therapy.This article reviews the progress of AXL and tumor.

Key words: Receptor tyrosine kinase, AXL, Tumor, AXL kinase inhibitors

中图分类号:

唐小崧综述，陈公琰审校. 受体酪氨酸激酶AXL在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2017, 31(3): 281-284.

TANG Xiaosong,CHEN Gongyan. Research progress of receptor tyrosine kinase AXL in tumor[J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(3): 281-284.

参考文献

1 Mukherjee SK,Wilhelm A,Antoniades CG.TAM receptor tyrosine kinase function and the immunopathology of liver disease[J].Am J Physiol Gastrointest Liver Physiol,2016,310(11):899-905.
2 Graham DK,DeRyckere D,Davies KD,et al.The TAM family:phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer[J].Nat Rev Cancer,2014,14(12):769-785.
3 Subramanian M,Hayes CD,Thome JJ,et al.An AXL/LRP-1/RANBP9 complex mediates DC efferocytosis and antigen cross-presentation in vivo[J].J Clin Invest,2014,124(3):1296-1308.
4 Meyer AS,Zweemer AJ,Lauffenburger DA.The AXL Receptor is a sensor of ligand spatial heterogeneity[J].Cell Syst,2015,1(1):25-36.
5 Levin PA,Brekken RA,Byers LA,et al.AXL receptor axis:A new therapeutic target in lung cancer[J].Thorac Oncol,2016,11(8):1357-1362.
6 Li Y,Ye X,Tan C,et al.AXL as a potential therapeutic target in cancer:role of AXL in tumor growth,metastasis and angiogenesis[J].Oncogene,2009,28(39):3442-3455.
7 Paolino M,Choidas A,Wallner S,et al.The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells[J].Nature,2014,507(7493):508-512.
8 Wu F,Li J,Jang C,et al.The role of AXL in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma[J].Int J Clin Exp Pathol,2014,7(10):6653-6661.
9 Scaltriti M,Elkabets M,Baselga J.Molecular pathways:AXL,a membrane receptor mediator of resistance to therapy[J].Clin Cancer Res,2016,22(6):1313-1317.
10 Sawabu T,Seno H,Kawshiima T,et al.Growth arrest-specific gene 6 and signaling enhances gastric cancer cell survival via Akt pahway[J].Mol Carcino,2007,46(2):155-164.
11 Cackowski FC,Eber MR,Rhee J,et al.Mer tyrosine kinase regulates disseminated prostate cancer cellular dormancy[J].J Cell Biochem,2016,9999:1-12.
12 Yung Y,Decker AM,Wang J,et al.Endogenous GAS6 and Mer receptor signaling regulate prostate cancer stem cells in bone marrow[J].Oncotarget,2016,7(18):25698-25711.
13 Cui ZL,Han FF,Peng XH,et al.YES-associated protein 1 promotes adenocarcinoma growth and metastasis through activation of the receptor tyrosine kinase AXL[J].Int J Immunopathol Pharmacol,2012,25(4):989-1001.
14 Choi YJ,Kim SY,So KS,et al.AUY922 effectively overcomes MET-and AXL-mediated resistance to EGFR-TKI in lung cancer cells[J].PLoS One,2015,10(3):e0119832.
15 Zhang YX,Knyazev PG,Cheburkin YV,et al.AXL is a potential target for therapeutic intervention in breast cancer progression[J].Cancer Res,2008,68(6):1905-1915.
16 Mudduluru G,Ceppi P,Kumarswamy R,et al.Regulation of AXL receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer[J].Oncogene,2011,30(25):2888-2899.
17 Wang XP,Saso H,Iwamoto T,et al.TIG1 Promotes the development and progression of inflammatory breast cancer through activation of AXL kinase[J].Cancer Res,2013,73(21):6516-6525.
18 Paccez JD,Vasques GJ,Correa RG,et al.The receptor tyrosine kinase AXL is an essential regulator of prostate cancer proliferation and tumor growth and represents a new therapeutic target[J].Oncogene,2013,32(6):689-698.
19 Wilson C,Ye X,Pham T,et al.AXL inhibition sensitizes mesenchymal cancer cells to antimitotic drugs[J].Cancer Res,2014,74(20):5878-5890.
20 Byers LA,Diao L,Wang J,et al.An epithelial mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies AXL as a therapeutic target for overcoming EGFR inhibitor resistance[J].Clin Cancer Res,2013,19(1):279-290.
21 Scaltriti M,Elkabets M,Baselga J.Molecular pathways:AXL,a membrane receptor mediator of resistance to therapy[J].Clin Cancer Res,2016,22(6):1313-1317.
22 Wu W,Bi C,Credille KM,et al.Inhibition of tumor growth and metastasis in non-small cell lung cancer by LY2801653,an inhibitor of several oncokinases,including MET[J].Clin Cancer Res,2013,19(20):5699-5710.
23 Burbridge MF,Bossard CJ,Saunier C,et al.S49076 Is a novel kinase inhibitor of MET,AXL,and FGFR with strong preclinical activity alone and in association with bevacizumab[J].Mol Cancer Ther,2013,12(9):1749-1762.
24 Myers SH,Brunton VG,Unciti-Broceta A.AXL inhibitors in cancer:a medicinal chemistry perspective[J].Med Chem,2015,59(8):3593-3608.
25 Sheridan C.First AXL inhibitor enters clinical trials[J].Nat Biotechnol,2013,31(9):775-776.
26 Esposito CL,Cerchia L,Catuogno S,et al.Multifunctional aptamer-miRNA conjugates for targeted cancer therapy[J].Mol Ther,2014,22(6):1151-1163.
27 安然,胡博,郎小玲,等.靶向AXL 药物在癌症治疗中的研究进展[J].国际药学研究杂志,2016,43(3):420-424.

[1]	孙力超,杨婧,孙立新,张媛,杨治华,冉宇靓. 采用肝癌球体细胞筛选鉴定识别肝癌干细胞的单抗[J]. 实用肿瘤学杂志, 2019, 33(3): 193-199.
[2]	张佳文,于雁,张薇,曹京燕,罗雯,尚利华. 基于UPLC-TOF/MS的小细胞肺癌患者血清代谢组学研究[J]. 实用肿瘤学杂志, 2019, 33(3): 200-205.
[3]	张茂祥,孙惠昕,宋冰冰. 2008—2012年哈尔滨市道里区恶性肿瘤发病与死亡分析[J]. 实用肿瘤学杂志, 2019, 33(3): 261-265.
[4]	刘乙澍,曲国蕃. 长链非编码RNA在骨肉瘤中的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 266-270.
[5]	侯玉雪,李晓莉. Wnt7a与恶性肿瘤的关系及研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 271-275.
[6]	朱琳,张春霞. 纳米载药系统靶向肿瘤干细胞的研究进展[J]. 实用肿瘤学杂志, 2019, 33(3): 276-279.
[7]	徐晖, 李希, 周春水. 应用以人转录组为靶点的shRNA文库筛选肺癌肿瘤相关抑制基因[J]. 实用肿瘤学杂志, 2019, 33(2): 97-102.
[8]	李诚, 兰莉, 杨超, 张婷婷, 王蕊, 林琳, 田文静. 2015—2017年哈尔滨市恶性肿瘤发病与死亡特征分析[J]. 实用肿瘤学杂志, 2019, 33(1): 62-66.
[9]	丁界先, 张津, 陈永刚, 王兴文综述, 王栓科审校. Wnt信号通路与肿瘤发生的研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 73-77.
[10]	于芳, 赵培. TRAP1在食管癌发展中的作用及机制研究[J]. 实用肿瘤学杂志, 2018, 32(6): 515-519.
[11]	王亚龙, 吕章艳, 张帆, 冯小双, 魏锣沛, 李鑫, 温艳, 高禹舜, 薛奇, 高树庚, 谭锋维. 人乳头状瘤病毒感染与肺癌预后相关性的Meta分析[J]. 实用肿瘤学杂志, 2018, 32(6): 520-526.
[12]	唐淑丽, 何匡邦, 张纯慧, 程佳楠, 张艳桥. 胃癌组织中miR-320a和CYLD的表达及与临床病理特征及预后的关系[J]. 实用肿瘤学杂志, 2018, 32(6): 538-544.
[13]	阚钧, 周岱翰综述, 张恩欣审校. 肿瘤合并心血管疾病的研究进展[J]. 实用肿瘤学杂志, 2018, 32(6): 558-561.
[14]	顾琦晟综述, 李继坤审校. 锰超氧化物歧化酶在肿瘤发生发展过程中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(6): 562-566.
[15]	刘娟综述, 张澍田审校. 细胞周期蛋白依赖性激酶抑制因子3在肿瘤中的研究进展[J]. 实用肿瘤学杂志, 2018, 32(6): 575-578.